MedTrace Logo

Pharmacogenetic and Pharmacokinetic Study of Clopidogrel

NCT01968499 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1805

Last updated 2017-10-18

No results posted yet for this study

Summary

This registration study aims to investigate the associations of the pharmacogenetic and pharmacokinetic factors with clopidogrel low response and clinical outcome in patients with coronary artery disease, and provide new pharmacogenetic and pharmacokinetic targets for the individualized anti-platelet treatment.

Conditions

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Chunjian Li, Ph.D · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2017-10-17
Completion
2017-10-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968499 on ClinicalTrials.gov